Patents by Inventor James Good
James Good has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12384764Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl or —NHR8; either (i), a, c and c are all bonds, with, b, d and f absent; or b, d, and f are all bonds, with a, c, and c absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is —OR8, —NR8R9 or —R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; n is 1 or 2; and one of V, W and X is N or CH and the other two are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: GrantFiled: November 2, 2020Date of Patent: August 12, 2025Assignee: Pfizer Inc.Inventors: Matthew Barrett, George Stuart Cockerill, James Good
-
Patent number: 12227507Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, and are bonds, and and are absent; or (ii) T is C, Z is N, and are bonds, and and are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7, —COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: GrantFiled: August 20, 2020Date of Patent: February 18, 2025Assignee: Pfizer Inc.Inventors: George Stuart Cockerill, James Good, Craig Alex Avery, Andrew Joseph Warner, Edward James Cochrane
-
Publication number: 20240173332Abstract: Pharmacuetical Compounds Benzodiazepine derivatives of formula (I): wherein: R1 is H or F; R2 is selected from formula (II) and formula (III) R3 is C1-C6 alkyl which is unsubstituted or substituted by CF3, or is a monocyclic 4- to 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S; R4 is H or a group selected from —X, -alk-X, —CONR6R7, C?NNR6R7, —SO2R6 and —SO2NR6R7; R4 is a group selected from —X, -alk-X, —CONR6R7, —C?NNR6R7, —SO2R6 and —SO2R6R7; X is OH or a derivative of an OH group selected from ?-amino carboxylic acid esters, carboxylic acid esters, carbonates, carbamates, ethers and phosphates: alk is C1-C6 alkylene which is unsubstituted or substituted by C3-C6 cycloalkyl; and R6 and R7 are each independently C1-C6 alkyl or C3-C6 cycloalkyl; and the pharmaceutically acceptable salts thereof are inhibitors of respiratory syncytial virus (RSV) and can therefore be used to treat or prevent an RSV infection.Type: ApplicationFiled: February 24, 2022Publication date: May 30, 2024Applicant: Pfizer Inc.Inventors: Matthew Barrett, Alexandre Bedernjak, George Stuart Cockerill, James Good
-
Publication number: 20230365585Abstract: Benzodiazepine derivatives of formula (Ib) wherein: R1 is H or halo; Y is selected from O, S, SO, SO2 and NR; one or two of V, W and X is or are N or CH and the other one or two is or are CH; R2 is a group selected from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, halo, —OR, —NHR?, —SOmNR2, —SOmR, nitro, —CO2R, —CN, —CONR2, —NHCOR and —NR11R12; each R is independently H or C1-C6 alkyl; R11 and R12 are each independently H or C1-C6 alkyl; or R11 and R12 form, together with the N atom to which they are attached, either (a) a morpholine ring which is optionally bridged by a —CH2— group linking two ring carbon atoms that are positioned para to each other, or (b) a spiro group of the following formula (b): R? is C3-C6 cycloalkyl; m is 1 or 2; n is 0, 1 or 2; and each of R3 to R10 is independently selected from H, C1-C6 alkyl, halo, —OR, -NR2,—NHR?, —SOmNR2, —SOmR, nitro, —CO2R, —CN, —CONR2, —NHCOR, —NR13R 4 whereinR13 and R14 form, together with the N atom to which they are attached, a morpholine ring, and thType: ApplicationFiled: July 7, 2021Publication date: November 16, 2023Inventors: Matthew BARRETT, George Stuart COCKERILL, James GOOD, Craig Alex AVERY, Edward James COCHRANE, Stuart Thomas ONIONS, Andrew Joseph WARNER
-
Publication number: 20230270751Abstract: Benzodiazepine derivatives of formula (Ie) wherein one R1 and R2 is a benzodiazepinyl-containing group of formula (II) in which R8 is H or halo; the other of R1 and R2 is a group Z selected from H, C3-C6 cycloalkyl, halo, —NHR9, benzyl, phenyl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, wherein phenyl, heterocyclyl and heteroaryl are unsubstituted or substituted by one or two substituents selected from 4- to 10-membered heterocyclyl which is unsubstituted or substituted by OR, and from C1-C6 alkyl, C1-C6 hydroxyalkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, halo, —OR, —(CH2)mOR, —NR2, —(CH2)mNR2, —NHR?, —SOmNR2, —SOmR, —SR, nitro, —CO2R, —CN, —CONR2, —NHCOR, —CH2NR10R11 and —NR10R11, in which each R is independently H or C1-C6 alkyl, R? is C3-C6 cycloalkyl and m is 1 or 2; R9 is selected from phenyl and 4- to 10-membered heteroaryl wherein phenyl and heteroaryl are unsubstituted or substituted by halo; R10 and R11 are each independently H or C1-C6 alkyl; or R10 and R11 form, together with theType: ApplicationFiled: July 7, 2021Publication date: August 31, 2023Inventors: Matthew BARRETT, George Stuart COCKERILL, James GOOD, Craig Alex AVERY, Edward James COCHRANE, Stefan Paul JONES, Stuart Thomas ONIONS, Andrew Joseph WARNER
-
Patent number: 11634425Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, -a- and -c- are bonds, and -b- and -d- are absent; or (ii) T is C, Z is N, -b- and -d- are bonds, and -a- and -c- are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7—COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: GrantFiled: June 21, 2022Date of Patent: April 25, 2023Assignee: PFIZER INC.Inventors: George Stuart Cockerill, James Good, Edward James Cochrane
-
Publication number: 20220409629Abstract: Benzodiazepine derivatives of formula (I): wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl, —NHR8 or —OR?; either (i) a, c, and e are all bonds, with b, d and f absent; orb, d and f are all bonds, with a, c and e absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is —OR8, —NR8R9 or —R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R? is H or C1-C6 alkyl; and one of V and W is CH and the other is N or CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: ApplicationFiled: October 22, 2020Publication date: December 29, 2022Inventors: MATTHEW BARRETT, GEORGE STUART COCKERILL, JAMES GOOD, CRAIG ALEX AVERY, EDWARD JAMES COCHRANE
-
Publication number: 20220380349Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl or —NHR8; either (i), a, c and c are all bonds, with, b, d and f absent; orb, d, and f are all bonds, with a, c, and c absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is —OR8, —NR8R9 or —R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; n is 1 or 2; and one of V, W and X is N or CH and the other two are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infectionType: ApplicationFiled: November 2, 2020Publication date: December 1, 2022Inventors: MATTHEW BARRETT, GEORGE STUART COCKERILL, JAMES GOOD
-
Publication number: 20220324873Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, —a— and —c— are bonds, and —b— and —d— are absent; or (ii) T is C, Z is N, —b— and —d— are bonds, and —a— and —c— are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7—COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C-6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: ApplicationFiled: June 21, 2022Publication date: October 13, 2022Inventors: GEORGE STUART COCKERILL, JAMES GOOD, CRAIG ALEX AVERY, EDWARD JAMES COCHRANE, ANDREW JOSEPH WARNER
-
Publication number: 20220306639Abstract: Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; either (i) T is N, Z is C, and are bonds, and and are absent; or (ii) T is C, Z is N, and are bonds, and and are absent; each of R3 and R4 is independently halo, —OR6, —NR6R7, —COR8, —C(O)OR8, —CON(R8)2 or —R6; R5 is H or halo; each of R6 and R7 is independently H or a group selected from C1-C6 alkyl, C3-C10 cycloalkyl, C6-C10 aryl, 4- to 10-membered heterocyclyl and 4- to 10-membered heteroaryl, the group being unsubstituted or substituted; R8 is H or C1-C6 alkyl, each R8 being the same or different when two are present; n is 0 or 1; and one of V, W, X and Y is N or CH and the other three are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: ApplicationFiled: August 20, 2020Publication date: September 29, 2022Inventors: George Stuart COCKERILL, James GOOD, Craig Alex AVERY, Edward James COCHRANE, Andrew Joseph WARNER
-
Patent number: 11141406Abstract: Benzimidazole derivatives of formula (I): (Formula (I)) wherein: R1 is —(CH2)m—R7, (Formula (II)) or (Formula (III)); R2 is H, halo, —(CH2)m—NH2, —(CH2)n—C(?NH)—NH2 or —(CH2)n—NH—(CH2)m—NHR9; R3 is H, F or Cl; each of R4, R5 and R6 is independently H or F; R7 is C1-C6 alkyl, CF3, —SO2R11, —NH—(CH2)2—(NH)r—R8, —NH—CH(R8R9) or a group of the following formula (A): (Formula (A)): W is —(CH2)m—, —CH2—O—CH2—, —CH2—S—CH2—, —(CH2)r—S(O)2—CH2— or —(CH2)r—NR8—CH2—; m is an integer of 1 to 3; n is 1 or 2; p is 1 and V is CH; or p is 0 and V is N; q is 0 or 1; r is 0 or 1; R8 is H, —SO2R11, —SO2CF3, —COR11, —C(O)OR11, —CON(R9)2 or —(CH2)nSO2R11; R9 is H or C1-C6 alkyl, each R9 being the same or different when two are present; R10 is —SO2R11, —SO2CF3, —COR11, —CON(R9)2 or —(CH2)nSO2R11; and R11 is C1-C6 alkyl; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: GrantFiled: December 21, 2018Date of Patent: October 12, 2021Assignee: REVIRAL LIMITEDInventor: James Good
-
Patent number: 11078189Abstract: Benzimidazole derivatives of formula (I): wherein: R1 is —(CH2)m-R4 or R2 is halo, —(CH2)m—NH2 or —(CH2)n—C(?NH)—NH2; R3 is H or F; R4 is —NH—(CH2)2—(NH)r—R5, —NH—(CHR5R6) or a group of the following formula (A): (A) W is —(CH2)m—, —CH2—O—CH2—, —CH2—S—CH2—, —(CH2)r—S(O)2—CH2— or —(CH2)r—NR5—CH2—; m is an integer of 1 to 3; n is 1 or 2; p is 1 and V is CH; or p is O and V is N; q is 0 or 1; r is 0 or 1; R5 is H, —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; R6 is H or C1-C6 alkyl; and R7 is —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: GrantFiled: July 20, 2018Date of Patent: August 3, 2021Assignee: REVIRAL LIMITEDInventors: Stuart George Cockerill, James Good
-
Publication number: 20200316030Abstract: Benzimidazole derivatives of formula (I): (Formula (I)) wherein: R1 is —(CH2)m—R7, (Formula (II)) or (Formula (III)); R2 is H, halo, —(CH2)m—NH2, —(CH2)n—C(?NH)—NH2 or —(CH2)n—NH—(CH2)m—NHR9; R3 is H, F or Cl; each of R4, R5 and R6 is independently H or F; R7 is C1-C6 alkyl, CF3, —SO2R11, —NH—(CH2)2—(NH)r—R8, —NH—CH(R8R9) or a group of the following formula (A): (Formula (A)): W is —(CH2)m, —CH2—O—CH2—, —CH2—S—CH2—, —(CH2)r—S(O)2—CH2— or —(CH2)r—NR8—CH2—; m is an integer of 1 to 3; n is 1 or 2; p is 1 and V is CH; or p is 0 and V is N; q is 0 or 1; r is 0 or 1; R is H, —SO2R11, —SO2CF3, —COR11, —C(O)OR11, —CON(R9)2 or —(CH2)nSO2R11; R9 is H or C1-C6 alkyl, each R9 being the same or different when two are present; R10 is —SO2R11, —SO2CF3, —COR11, —CON(R9)2 or —(CH2)nSO2R11; and R11 is C1-C6 alkyl; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: ApplicationFiled: December 21, 2018Publication date: October 8, 2020Inventor: James GOOD
-
Publication number: 20200172515Abstract: Benzimidazole derivatives of formula (I): wherein: R1 is —(CH2)m-R4 or R2 is halo, —(CH2)m—NH2 or —(CH2)n—C(?NH)—NH2; R3 is H or F; R4 is —NH—(CH2)2—(NH)r—R5, —NH—(CHR5R6) or a group of the following formula (A): (A) W is —(CH2)m—, —CH2—O—CH2—, —CH2—S—CH2—, —(CH2)r—S(O)2—CH2— or —(CH2)r—NR5—CH2—; m is an integer of 1 to 3; n is 1 or 2; p is 1 and V is CH; or p is O and V is N; q is 0 or 1; r is 0 or 1; R5 is H, —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; R6 is H or C1-C6 alkyl; and R7 is —SO2Me, —SO2Et, —SO2CF3, —COMe, —CONMe2, —CONH2 or —CH2CH2SO2Me; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.Type: ApplicationFiled: July 20, 2018Publication date: June 4, 2020Inventors: Stuart George Cockerill, James Good
-
Publication number: 20170233409Abstract: Described are compounds, compositions, and methods for treating or preventing conditions or disorders caused by or associated with bacterial type IV secretion systems.Type: ApplicationFiled: February 17, 2017Publication date: August 17, 2017Inventors: Maria Hadjifrangiskou, Fredrik Almqvist, Carrie L. Shaffer, James Good
-
Publication number: 20140002233Abstract: A device for monitoring and controlling the operation of an individual piece of Utilization Equipment or an Alternate Electrical Source, the Module linked to an individual piece of Utilization Equipment or an Alternate Electrical Source via a Docking Apparatus.Type: ApplicationFiled: February 15, 2012Publication date: January 2, 2014Applicant: INTERACTIVE CONTROL SOLUTIONS, LLCInventors: Ronald J Miller, James Good
-
Publication number: 20130311146Abstract: A system for designing, configuring, and reconfiguring operational relationships between one or more wireless control modifies within a controlled environment that are linked to pieces of utilization equipment or to an alternate electrical source, and one or more wireless control devices within a controlled environment. The system comprises application software and a database which interfaces with computer-aided design (CAD) software and with energy management systems.Type: ApplicationFiled: January 25, 2012Publication date: November 21, 2013Applicant: INTERACTIVE CONTROL SOLUTIONS, LLCInventors: Ronald J. Miller, James Good
-
Publication number: 20030124192Abstract: The invention provides the use of a hemicellulose for the manufacture of a composition for use as a vaccine adjuvant. The hemicellulose is preferably an arabinoxylan and more preferably is a crosslinked arabinoxylan such as arabinoxylan ferrulate. Also provided by the invention are vaccine compositions containing a vaccine antigen, or a DNA vaccine, and the hemicellulose, preferably in crosslinked microparticulate form.Type: ApplicationFiled: September 25, 2002Publication date: July 3, 2003Inventors: Colin Stanley Fitchett, Jodie Hadley, Richard Le Page, James Good, Christopher Coward